![]() |
Name |
Lamellicolic anhydride
|
Molecular Formula | C13H8O6 | |
IUPAC Name* |
2,4,12-trihydroxy-8-methyl-3-oxatricyclo[7.3.1.05,13]trideca-1,4,7,9(13),11-pentaene-6,10-dione
|
|
SMILES |
CC1=CC(=O)C2=C(OC(=C3C2=C1C(=O)C=C3O)O)O
|
|
InChI |
InChI=1S/C13H8O6/c1-4-2-5(14)9-11-8(4)6(15)3-7(16)10(11)13(18)19-12(9)17/h2-3,16-18H,1H3
|
|
InChIKey |
NVARQLOCVDEUPQ-UHFFFAOYSA-N
|
|
Synonyms |
Lamellicolic anhydride; 41758-46-7
|
|
CAS | NA | |
PubChem CID | 135779135 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 260.2 | ALogp: | 0.3 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 19 | QED Weighted: | 0.567 |
Caco-2 Permeability: | -5.258 | MDCK Permeability: | 0.00000432 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.011 |
Human Intestinal Absorption (HIA): | 0.095 | 20% Bioavailability (F20%): | 0.016 |
30% Bioavailability (F30%): | 0.935 |
Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 81.11% |
Volume Distribution (VD): | 0.887 | Fu: | 15.08% |
CYP1A2-inhibitor: | 0.828 | CYP1A2-substrate: | 0.24 |
CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.053 |
CYP2C9-inhibitor: | 0.19 | CYP2C9-substrate: | 0.294 |
CYP2D6-inhibitor: | 0.095 | CYP2D6-substrate: | 0.144 |
CYP3A4-inhibitor: | 0.036 | CYP3A4-substrate: | 0.023 |
Clearance (CL): | 1.248 | Half-life (T1/2): | 0.745 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.095 |
Drug-inuced Liver Injury (DILI): | 0.954 | AMES Toxicity: | 0.207 |
Rat Oral Acute Toxicity: | 0.099 | Maximum Recommended Daily Dose: | 0.26 |
Skin Sensitization: | 0.854 | Carcinogencity: | 0.082 |
Eye Corrosion: | 0.064 | Eye Irritation: | 0.756 |
Respiratory Toxicity: | 0.273 |